Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study

National comprehensive Cancer Network. Prostate cancer (version 1.2023). 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Grubmuller, 2018, PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact, Clin Cancer Res, 24, 6300, 10.1158/1078-0432.CCR-18-0768 Christ, 2022, Imaging-based prevalence of oligometastatic disease: a single-center cross-sectional study, Int J Radiat Oncol Biol Phys, 114, 596, 10.1016/j.ijrobp.2022.06.100 Ayati, 2023, More accurate imaging is not stage migration: time to move from “hubble” to “webb” in hormone-sensitive prostate cancer, Eur Urol, 83, 6, 10.1016/j.eururo.2022.10.005 Dai, 2022, Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial, Eur Urol Oncol, 5, 519, 10.1016/j.euo.2022.06.001 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 Bernard, 2016, Approach to oligometastatic prostate cancer, Am Soc Clin Oncol Educ Book, 36, 119, 10.1200/EDBK_159241 Rogowski, 2021, Radiotherapy of oligometastatic prostate cancer: a systematic review, Radiat Oncol, 16, 50, 10.1186/s13014-021-01776-8 O'Shaughnessy, 2017, A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer, Urology, 102, 164, 10.1016/j.urology.2016.10.044 Yanagisawa, 2022, Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis, Eur Urol, 82, 584, 10.1016/j.eururo.2022.08.002 Heidenreich, 2020, Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease, Curr Opin Urol, 30, 90, 10.1097/MOU.0000000000000691 Heidenreich, 2018, Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases, Eur Urol Oncol, 1, 46, 10.1016/j.euo.2018.03.002 Gandaglia, 2017, Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up, Eur Urol, 72, 289, 10.1016/j.eururo.2016.08.040 Rajwa, 2023, Cytoreductive radical prostatectomy for metastatic hormone-sensitive prostate cancer— evidence from recent prospective reports, Eur Urol Focus, 9, 637, 10.1016/j.euf.2023.01.011 Fonseca, 2022, Genomic features of lung-recurrent hormone-sensitive prostate cancer, JCO Precis Oncol, 6, e2100543, 10.1200/PO.21.00543 Fendler, 2023, PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0, Eur J Nucl Med Mol Imaging, 50, 1466, 10.1007/s00259-022-06089-w Barentsz, 2016, Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use, Eur Urol, 69, 41, 10.1016/j.eururo.2015.08.038 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Rabbani, 2010, Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy, Eur Urol, 57, 371, 10.1016/j.eururo.2009.11.034 Dindo, 2004, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 240, 205, 10.1097/01.sla.0000133083.54934.ae Porpiglia, 2013, Randomised controlled trial comparing laparoscopic and robot-assisted radical prostatectomy, Eur Urol, 63, 606, 10.1016/j.eururo.2012.07.007 Vittinghoff, 2007, Relaxing the rule of ten events per variable in logistic and Cox regression, Am J Epidemiol, 165, 710, 10.1093/aje/kwk052 Peduzzi, 1995, Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates, J Clin Epidemiol, 48, 1503, 10.1016/0895-4356(95)00048-8 Mandel, 2021, Enumeration and changes in circulating tumor cells and their prognostic value in patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer—translational research results from the prospective ProMPT trial, Eur Urol Focus, 7, 55, 10.1016/j.euf.2019.05.008 Sooriakumaran, 2016, A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation, Eur Urol, 69, 788, 10.1016/j.eururo.2015.05.023 Wilt, 2017, Follow-up of prostatectomy versus observation for early prostate cancer, N Engl J Med., 377, 132, 10.1056/NEJMoa1615869 Lei, 2015, Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer, Sci Rep, 5, 7713, 10.1038/srep07713 Zelefsky, 2010, Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix, J Clin Oncol, 28, 1508, 10.1200/JCO.2009.22.2265 Buelens, 2022, Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study), BJU Int, 129, 699, 10.1111/bju.15553 Evans, 2018, Treatment effects in prostate cancer, Mod Pathol, 31, 110, 10.1038/modpathol.2017.158 Pompe, 2018, Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems, BJU Int, 122, 801, 10.1111/bju.14369 Gandaglia, 2017, Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally-advanced prostate cancer, Eur Urol, 71, 249, 10.1016/j.eururo.2016.05.008 Mottet N, Conford P, van den Bergh RCN, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. EAU Guidelines Office; 2022. https://uroweb.org/guidelines/prostate-cancer. Dhiantravan, 2021, Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy, Eur Urol Focus, 7, 234, 10.1016/j.euf.2020.09.021 Rajwa, 2022, Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis, Eur Urol, 82, 82, 10.1016/j.eururo.2022.03.031 Rajwa, 2023, Surgical metastasectomy for visceral and bone prostate cancer metastases: a mini-review, Eur Urol Focus, 9, 232, 10.1016/j.euf.2022.10.013 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Hussain, 2006, Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162), J Clin Oncol, 24, 3984, 10.1200/JCO.2006.06.4246 Choueiri, 2009, Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy, Cancer, 115, 981, 10.1002/cncr.24064 Esen, 2023, Prostate-specific membrane antigen positron emission tomography as a biomarker to assess treatment response in patients with advanced prostate cancer, Eur Urol Focus, 9, 596, 10.1016/j.euf.2023.02.001